Leukocyte-Derived Interleukin-10 Aggravates Postoperative Ileus

Objective: Postoperative ileus (POI) is an inflammation-mediated complication of abdominal surgery, characterized by intestinal dysmotility and leukocyte infiltration into the muscularis externa (ME). Previous studies indicated that interleukin (IL)-10 is crucial for the resolution of a variety of inflammation-driven diseases. Herein, we investigated how IL-10 affects the postoperative ME inflammation and found an unforeseen role of IL-10 in POI. Design: POI was induced by a standardized intestinal manipulation (IM) in C57BL/6 and multiple transgenic mouse strain including C-C motif chemokine receptor 2^-/-, IL-10^-/-, and LysM^cre/IL-10^fl/fl mice. Leukocyte infiltration, gene and protein expression of cytokines, chemokines, and macrophage differentiation markers as well as intestinal motility were analyzed. IL-10 serum levels in surgical patients were determined by ELISA. Results: IL-10 serum levels were increased in patient after abdominal surgery. In mice, a complete or leucocyte-restricted IL-10 deficiency ameliorated POI and reduced the postoperative ME neutrophil infiltration. Infiltrating monocytes were identified as main IL-10 producers and undergo IL-10-dependent M2 polarization. Interestingly, M2 polarization is not crucial to POI development as abrogation of monocyte infiltration did not prevent POI due to a compensation of the IL-10 loss by resident macrophages and neutrophils. Organ culture studies demonstrated that IL-10 deficiency impeded neutrophil migration toward the surgically traumatized ME. This mechanism is mediated by reduction of neutrophil attracting chemokines. Conclusion: Monocyte-derived macrophages are the major IL-10 source during POI. An IL-10 deficiency decreases the postoperative expression of neutrophil-recruiting chemokines, consequently reduces the neutrophil extravasation into the postsurgical bowel wall, and finally protects mice from POI.

Risk Factors for Severe Complications in Ovarian Cancer Surgery

Backround: Due to extensive surgical intervention for macroscopic complete cytoreduction in epithelial ovarian cancer (EOC) patients, severe complications in the postoperative course are possible.

PATIENTS AND METHODS

A total of 345 EOC patients who underwent cytoreductive surgery were retrospectively evaluated regarding risk factors for an unfavorable postoperative course. Possible pre-, intra- and postoperative risk factors were statistically analyzed performing multivariate ordinal logistic regression.

RESULTS

A total of 345 EOC patients underwent cytoreductive surgery. There were no complications in 114 patients, mild complications in 114 patients and severe complications in 117 patients. The risk factor evaluation identified age (p=0.049), smoking (p=0.032) and duration of surgery (p<0.0001) as significant factors for severe postoperative morbidity.

CONCLUSION

In EOC patients age, smoking and the duration of surgery have significant impact on the postoperative course. Only the duration of surgery can be positively influenced by a well-trained EOC team.

Ergebnisse nach prophylaktischer totaler Gastrektomie bei erblichem diffusem Magenkrebs

Hintergrund Die prophylaktische totale Gastrektomie ist die Therapie der Wahl bei Patienten mit nachgewiesener pathogener Keimbahnmutation im CDH1-Gen und hierdurch hohem Risiko für die Entwicklung eines diffusen hereditären Magenkarzinoms (HDGC). Minimalinvasive Operationsverfahren wurden in den letzten Jahren im Bereich der onkologischen Magenchirurgie etabliert.

Patienten und Methoden Insgesamt 12 Patienten wurden zwischen 2013 und März 2018 in unserem Zentrum für erbliche Tumorerkrankungen aufgrund einer nachgewiesenen CDH1-Keimbahnmutation betreut und in unserer Klinik prophylaktisch gastrektomiert. Die perioperativen Ergebnisse wurden in einer Datenbank prospektiv erfasst.

Ergebnisse Es erfolgte in 5 Fällen eine offene (Zeitraum: 2013 – 2015) und in 7 Fällen eine minimalinvasive (Zeitraum: 2016 – 2017) prophylaktische Gastrektomie. Das mediane Alter im Gesamtkollektiv (7 Frauen und 5 Männer) lag bei 42 (19 – 60) Jahren. Die durchschnittliche Operationszeit betrug 291 ± 72 Minuten (offen: 269 ± 70; minimalinvasiv: 307 ± 75). Die perioperative 60-Tage-Mortalität und die Anastomoseninsuffizienzrate betrugen 0%. Bei 3 Patienten kam es zu postoperativen Komplikationen (jeweils einmal II, IIIa, IVb nach Clavien-Dindo-Klassifikation), entsprechend einer Morbidität von 25% (3/12). Die postoperative Liegedauer lag bei 14,5 ± 6,2 Tagen (offen: 16,2 ± 7,9; minimalinvasiv: 13,3 ± 5,0). Bei 10 Patienten (10/12; 83%) wurden in der histologischen Aufarbeitung intramukosale Karzinome (pT1a) diagnostiziert, 9 davon mit multifokaler Ausbreitung. Fortgeschrittene Karzinome (≥ pT1b) und Lymphknotenmetastasen lagen in keinem Fall vor.

Schlussfolgerung Patienten mit Verdacht auf ein erhöhtes Risiko für ein hereditäres diffuses Magenkarzinom sollten in einem interdisziplinären Zentrum für erbliche Tumorerkrankungen betreut werden. Die minimalinvasive (laparoskopische) prophylaktische totale Gastrektomie ist ein machbares und sicheres risikoreduzierendes Verfahren bei Patienten mit CDH1-Genmutation und erblichem Magenkrebs. Demzufolge sollte, bei fehlenden Kontraindikationen und vorhandener Expertise, die minimalinvasive Operation bei diesem speziellen Kollektiv das Standardverfahren sein.

Orthotopic small bowel transplantation in rats

Small bowel transplantation has become an accepted clinical option for patients with short gut syndrome and failure of parenteral nutrition (irreversible intestinal failure). In specialized centers improved operative and managing strategies have led to excellent short- and intermediate term patient and graft survival while providing high quality of life (1,3). Unlike in the more common transplantation of other solid organs (i.e. heart, liver) many underlying mechanisms of graft function and immunologic alterations induced by intestinal transplantation are not entirely known(6,7). Episodes of acute rejection, sepsis and chronic graft failure are the main obstacles still contributing to less favorable long term outcome and hindering a more widespread employment of the procedure despite a growing number of patients on home parenteral nutrition who would potentially benefit from such a transplant. The small intestine contains a large number of passenger leucocytes commonly referred to as part of the gut associated lymphoid system (GALT) this being part of the reason for the high immunogenity of the intestinal graft. The presence and close proximity of many commensals and pathogens in the gut explains the severity of sepsis episodes once graft mucosal integrity is compromised (for example by rejection). To advance the field of intestinal- and multiorgan transplantation more data generated from reliable and feasible animal models is needed. The model provided herein combines both reliability and feasibility once established in a standardized manner and can provide valuable insight in the underlying complex molecular, cellular and functional mechanisms that are triggered by intestinal transplantation. We have successfully used and refined the described procedure over more than 5 years in our laboratory (8-11). The JoVE video-based format is especially useful to demonstrate the complex procedure and avoid initial pitfalls for groups planning to establish an orthotopic rodent model investigating intestinal transplantation.

[Current recommendations for surveillance, risk reduction and therapy in Lynch syndrome patients]

INTRODUCTION

 Lynch syndrome (LS) is the most common hereditary colorectal cancer syndrome and accounts for ~3 % of all CRCs. This autosomal dominant disorder is caused by germline mutations in DNA mismatch repair genes (MLH1, MSH2, MSH6, PMS2, and EPCAM). One in 300 individuals of the general population are considered to be mutation carriers (300 000 individuals/Germany). Mutation carriers are at a high CRC risk of 15-46 % till the age of 75 years. LS also includes a variety of extracolonic malignancies such as endometrial, small bowel, gastric, urothelial, and other cancers.

METHODS

 The German Consortium for Familial Intestinal Cancer consists of 14 university centers in Germany. The aim of the consortium is to develop and evaluate surveillance programs and to further translate the results in clinical care. We have revisited and updated the clinical management guidelines for LS patients in Germany.

RESULTS

 A surveillance colonoscopy should be performed every 12-24 months starting at the age of 25 years. At diagnosis of first colorectal cancer, an oncological resection is advised, an extended resection (colectomy with ileorectal anastomosis) has to be discussed with the patient. The lifetime risk for gastric cancer is 0.2-13 %. Gastric cancers detected during surveillance have a lower tumor stage compared to symptom-driven detection. The lifetime risk for small bowel cancer is 4-8 %. About half of small bowel cancer is located in the duodenum and occurs before the age of 35 years in 10 % of all cases. Accordingly, patients are advised to undergo an esophagogastroduodenoscopy every 12-36 months starting by the age of 25 years.

CONCLUSION

 LS colonic and extracolonic clinical management, surveillance and therapy are complex and several aspects remain unclear. In the future, surveillance and clinical management need to be more tailored to gene and gender. Future prospective trials are needed.

A toolbox for a structured risk-based prehabilitation program in major surgical oncology

Prehabilitation is a multimodal concept to improve functional capability prior to surgery, so that the patients' resilience is strengthened to withstand any peri- and postoperative comorbidity. It covers physical activities, nutrition, and psychosocial wellbeing. The literature is heterogeneous in outcomes and definitions. In this scoping review, class 1 and 2 evidence was included to identify seven main aspects of prehabilitation for the treatment pathway: (i) risk assessment, (ii) FITT (frequency, interventions, time, type of exercise) principles of prehabilitation exercise, (iii) outcome measures, (iv) nutrition, (v) patient blood management, (vi) mental wellbeing, and (vii) economic potential. Recommendations include the risk of tumor progression due to delay of surgery. Patients undergoing prehabilitation should perceive risk assessment by structured, quantifiable, and validated tools like Risk Analysis Index, Charlson Comorbidity Index (CCI), American Society of Anesthesiology Score, or Eastern Co-operative Oncology Group scoring. Assessments should be repeated to quantify its effects. The most common types of exercise include breathing exercises and moderate- to high-intensity interval protocols. The program should have a duration of 3-6 weeks with 3-4 exercises per week that take 30-60 min. The 6-Minute Walking Testing is a valid and resource-saving tool to assess changes in aerobic capacity. Long-term assessment should include standardized outcome measurements (overall survival, 90-day survival, Dindo-Clavien/CCI®) to monitor the potential of up to 50% less morbidity. Finally, individual cost-revenue assessment can help assess health economics, confirming the hypothetic saving of $8 for treatment for $1 spent for prehabilitation. These recommendations should serve as a toolbox to generate hypotheses, discussion, and systematic approaches to develop clinical prehabilitation standards.

Multimodal and systemic therapy with cabozantinib for treatment of recurrent hepatocellular carcinoma after liver transplantation: A case report with long term follow-up outcomes

RATIONALE

Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) remains a major therapeutic challenge. In recent years, new molecular-targeted therapies, such as cabozantinib, have been approved for the treatment of advanced HCC. However, clinical experience with these new drugs in the treatment of HCC in the LT setting is very limited.

PATIENT CONCERNS

In 2003, a 36-year-old woman was referred to the hospital with right upper abdominal pain.

DIAGNOSIS

An initial ultrasound of the liver demonstrated a large unclear lesion of the left lobe of the liver. The magnet resonance imaging findings confirmed a multifocal inoperable HCC in a non-cirrhotic liver. Seven years after receiving a living donor LT, pulmonary and intra-hepatic recurrence of the HCC was radiologically diagnosed and histologically confirmed.

INTERVENTIONS

Following an interdisciplinary therapy concept consisting of surgical, interventional-radiological (with radiofrequency ablation [RFA]) as well as systemic treatment, the patient achieved a survival of more than 10 years after tumor recurrence. As systemic first line therapy with sorafenib was accompanied by grade 3 to 4 toxicities, such as mucositis, hand-foot skin reaction, diarrhea, liver dysfunction, and hyperthyroidism, it had to be discontinued. After switching to cabozantinib from June 2018 to April 2020, partial remission of all tumor manifestations was achieved. The treatment of the remaining liver metastasis could be completed by RFA. The therapy with cabozantinib was well tolerated, only mild arterial hypertension and grade 1 to 2 mucositis were observed. Liver transplant function was stable during the therapy, no drug interaction with immunosuppressive drugs was observed.

OUTCOMES

More than 10 years survival after recurrence of HCC after living-donor LT due to intensive multimodal therapy concepts, including surgery, RFA, and systemic therapy with cabozantinib in the second line therapy.

LESSONS

In conclusion, this report highlights the tolerability and effectiveness of cabozantinib for the treatment of HCC recurrence after LT. We show that our patient with a late recurrence of HCC after LT benefitted from intensive multimodal therapy concepts, including surgery, RFA, and systemic therapy.

[Imaging of the pelvic floor (MR defecography) : The surgeon's perspective]

BACKGROUND

Magnetic resonance defecography (MRD) plays a central role in diagnosing pelvic floor functional disorders by visualizing the entire pelvic floor along with pelvic organs and providing functional assessment of the defecation process. A shared understanding between radiology and surgery regarding indications and interpretation of findings is crucial for optimal utilization of MRD.

OBJECTIVES

This review aims to explain the indications for MRD from a surgical perspective and elucidate the significance of radiological findings for treatment. It intends to clarify for which symptoms MRD is appropriate and which criteria should be followed for standardized results. This is prerequisite to develop interdisciplinary therapeutic approaches.

MATERIALS AND METHODS

A comprehensive literature search was conducted, including current consensus guidelines.

RESULTS

MRD can provide relevant findings in the diagnosis of fecal incontinence and obstructed defecation syndrome, particularly in cases of pelvic floor descent, enterocele, intussusception, and pelvic floor dyssynergia. However, rectocele findings in MRD should be interpreted with caution in order to avoid overdiagnosis.

CONCLUSION

MRD findings should never be considered in isolation but rather in conjunction with patient history, clinical examination, and symptomatology since morphology and functional complaints may not always correlate, and there is wide variance of normal values. Interdisciplinary interpretation of MRD results involving radiology, surgery, gynecology, and urology, preferably in the context of pelvic floor conferences, is recommended.

Pharmacologic prevention and therapy of postoperative paralytic ileus after gastrointestinal cancer surgery: systematic review and meta-analysis

BACKGROUND

Postoperative paralytic ileus (POI) is a significant concern following gastrointestinal tumor surgery. Effective preventive and therapeutic strategies are crucial but remain elusive. Current evidence from randomized-controlled trials on pharmacological interventions for prevention or treatment of POI are systematically reviewed to guide clinical practice and future research.

MATERIALS AND METHODS

Literature was systematically searched for prospective randomized-controlled trials testing pharmacological interventions for prevention or treatment of POI after gastrointestinal tumor surgery. Meta-analysis was performed using a random effects model to determine risk ratios and mean differences with 95% CI. Risk of bias and evidence quality were assessed.

RESULTS

Results from 55 studies, involving 5078 patients who received experimental interventions, indicate that approaches of opioid-sparing analgesia, peripheral opioid antagonism, reduction of sympathetic hyperreactivity, and early use of laxatives effectively prevent POI. Perioperative oral Alvimopan or intravenous administration of Lidocaine or Dexmedetomidine, while safe regarding cardio-pulmonary complications, demonstrated effectiveness concerning various aspects of postoperative bowel recovery [Lidocaine: -5.97 (-7.20 to -4.74)h, P <0.0001; Dexmedetomidine: -13.00 (-24.87 to -1.14)h, P =0.03 for time to first defecation; Alvimopan: -15.33 (-21.22 to -9.44)h, P <0.0001 for time to GI-2 ] and length of hospitalization [Lidocaine: -0.67 (-1.24 to -0.09)d, P =0.02; Dexmedetomidine: -1.28 (-1.96 to -0.60)d, P =0.0002; Alvimopan: -0.58 (-0.84 to -0.32)d, P <0.0001] across wide ranges of evidence quality. Perioperative nonopioid analgesic use showed efficacy concerning bowel recovery as well as length of hospitalization [-1.29 (-1.95 to -0.62)d, P =0.0001]. Laxatives showed efficacy regarding bowel movements, but not food tolerance and hospitalization. Evidence supporting pharmacological treatment for clinically evident POI is limited. Results from one single study suggest that Neostigmine reduces time to flatus and accelerates bowel movements [-37.06 (-40.26 to -33.87)h, P <0.0001 and -42.97 (-47.60 to -38.35)h, P <0.0001, respectively] with low evidence quality.

CONCLUSION

Current evidence concerning pharmacological prevention and treatment of POI following gastrointestinal tumor surgery is limited. Opioid-sparing concepts, reduction of sympathetic hyperreactivity, and laxatives should be implemented into multimodal perioperative approaches.

[Robotic Assisted Proctocolectomy with Ileal Pouch-anal Anastomosis in Familial Adenomatous Polyposis - a Video Vignette]

Das kolorektale Karzinom (KRK) ist eines der häufigsten Malignome, bei dem in den letzten Jahren eine signifikante Zunahme hereditärer Fälle beobachtet werden konnte. Die zweithäufigste Ursache für ein hereditäres KRK ist die familiäre adenomatöse Polyposis, eine obligate Präkanzerose. Sinnvollster Therapieansatz ist eine prophylaktische laparoskopische Proktokolektomie mit Ileumpouch-analer Anastomose (IPAA) im jungen Erwachsenenalter. Mit der zunehmenden Etablierung robotischer Verfahren stellt sich die Frage, ob die Vorteile der robotischen Operationen, wie bspw. vereinfachtes Operieren und bessere Visualisierung in engen Räumen, insbesondere bei der prophylaktischen Proktokolektomie, sinnvoll sein kann. Problematisch ist allerdings die Notwendigkeit, in allen 4 Quadranten des Abdomens operieren zu müssen, was bei robotischen Eingriffen ein limitierender Faktor sein kann. Ziel dieser Arbeit war es daher, die Machbarkeit der robotisch assistierten Proktokolektomie mit IPAA zu demonstrieren und Tipps für eine Anwendung in der klinischen Praxis zu geben.

[The Devascularisation Procedure for the Treatment of Fundic and Oesophageal Varices in Portal Hypertension - a Retrospective Analysis of 55 Cases]

BACKGROUND

The most dangerous complication of portal hypertension is the formation of oesophageal varices, as the risk of bleeding is up to 80%. In order to reduce pressure reduction in the portosystemic circulation and as secondary prophylaxis, the TIPSS procedure has proven successful. In patients with portal vein thrombosis, portosystemic shunt surgery is possible to reduce the risk of variceal bleeding. However, if thrombosis of the mesentericoportal axis or hepatic encephalopathy is imminent, interventional or surgical creation of a portosystemic shunt is contraindicated. As a last resort to avoid recurrent bleeding or in case of inexorable bleeding, a devascularisation procedure may be indicated. The aim of this study was to investigate perioperative complications, morbidity and mortality, the incidence of postoperative recurrent bleeding, and patient survival after devascularisation surgery.

PATIENTS AND METHODS

We retrospectively analysed 55 patients with a history of variceal haemorrhage or acute bleeding without the possibility of an invasive or operative portosystemic shunt for complication rate, recurrent variceal recurrence, rebleeding and survival.

RESULTS

While complications for elective surgery were 61%, they increased significantly in emergency surgeries (75%, p = 0.002), especially for severe complications (Dindo/Clavien grade III - V° [14 vs. 58%, p = 0.002]). Devascularisation significantly reduced varicosis occurrence. Furthermore, only 16% of patients suffered recurrent bleeding in a follow-up period of up to 24 years. Median survival (MS) after devascularisation surgery was 169 ± 23 months. After elective surgery, MS was 194 ± 25 months, but after emergency surgery only 49 ± 16 months. No patient showed any hepatic encephalopathy during their hospital stay.

DISCUSSION

Devascularisation surgery is well suited for secondary prophylaxis in patients with fundic and oesophageal varices and portal hypertension with no possibility of portosystemic shunt or with impending hepatic encephalopathy. However, if the operation is performed in an emergency situation, significantly more major complications occur and the outcome is significantly worse. Therefore, especially in the absence of an opportunity of lowering pressure in the portal venous system and with progressive varices, elective devascularisation should be considered at an early stage.

[Late Complications of Permanent Intestinal Stomata]

INTRODUCTION

Complications following the creation of permanent intestinal ostomies are common and lead to serious problems in the stoma care of affected patients. The aim of this prospective, single-centre follow-up study was to record the rate of late complications in our own patient group and to identify potential risk factors.

METHODS

All patients who received a permanent intestinal ostomy in our clinic within the period 2006 - 2016 were included in the study. 50 patients gave their informed consent and participated in our follow-up (14 female [28%], 36 male [72%]). The analysis of stoma-associated complications was performed by review of medical records and a systematic follow-up (standardised questionnaire, clinical examination, and ultrasound of the abdominal wall).

RESULTS

Indications included malignancy (n = 27; 54%), anastomotic leakage (n = 10; 20%), acute diverticulitis (n = 7; 14%), IBD (n = 5; 10%) and rarer indications. The top 3 late complications were peristomal skin irritation (n = 25, 50%), parastomal hernia (n = 14; 28%) and prolapse (n = 9; 18%). Acute diverticulitis resulted in increased stomal retraction (p = 0.012). Double-barreled stomata were associated with increased herniation rates (p = 0.044) and prolapse (p = 0.047). Ileostomies were associated with peristomal skin irritation (p = 0.021). Age, sex or emergency stoma creation did not constitute independent risk factors for the development of late complications in our group of patients.

CONCLUSION

Professional pre- and postoperative stoma therapy and care includes preoperative marking of a stoma site and structured stoma-specific follow-up by stoma therapists, surgeons and general practitioners, as well as stringent and early treatment of structural complications. This can prevent and mitigate late complications of permanent intestinal stomata. Interestingly, stoma placement was not an independent risk factor for late complications in an emergency situation.